BI
EIGR

BVF Inc’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

BVF Inc’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,268
Closed -$463K – 64
2020
Q1 		$463K Sell
2,268
-2,518
-53% -$803K 0.04% 56
2019
Q4 		$2.14M Sell
4,786
-13,198
-73% -$4.68M 0.16% 49
2019
Q3 		$5.53M Sell
17,984
-4,516
-20% -$1.47M 0.58% 42
2019
Q2 		$7.16M Hold
22,500
– – 0.78% 37
2019
Q1 		$9.44M Hold
22,500
– – 1.06% 32
2018
Q4 		$6.86M Buy
+22,500
New +$7.27M 0.9% 33

Other funds holding EIGR

6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BVF Inc's EIGR Position: Q2 2020 in Review

BVF Inc sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2020, closing a stake of 2,268 shares — an estimated $463K sold.

BVF Inc first reported a position in EIGR in Q4 2018 and held it in 6 quarters. The position peaked at $9.44M in Q1 2019. 94 funds tracked by Wall St. Rank hold EIGR as of Q2 2020.

  • BVF Inc reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
  • BVF Inc sold 2,268 Eiger BioPharmaceuticals, Inc. shares in Q2 2020, an estimated $463K.
  • BVF Inc first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2018 and held it in 6 quarters.
  • BVF Inc's Eiger BioPharmaceuticals, Inc. position peaked at $9.44M in Q1 2019.
  • 94 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2020.

Based on BVF Inc's 13F filing for Q2 2020, filed 14 Aug 2020.